Actively Recruiting
Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis
Led by Tasly Pharmaceutical Group Co., Ltd · Updated on 2024-09-03
180
Participants Needed
12
Research Sites
96 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will evaluate the efficacy and safety of Jiuweihuaban Pill in the treatment of moderate to severe plaque psoriasis(syndrome of blood-heat ).
CONDITIONS
Official Title
Efficacy and Safety of Jiuweihuaban Pill for Treating Plaque Psoriasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 to 65 years, male or female
- Diagnosed with plaque psoriasis vulgaris according to western criteria
- Meets Traditional Chinese Medicine syndrome standards for blood-heat plaque psoriasis
- At screening: PASI score between 3 and 20, Body Surface Area (BSA) affected between 3% and 10%, and sPGA score of 2 or higher
- Willing to participate voluntarily and sign informed consent
You will not qualify if you...
- Psoriasis caused by drugs or non-plaque types such as guttate, arthropathic, pustular, erythrodermic, or lesions only in specific areas like face, scalp, nails, or mucous membranes
- Systemic non-biological therapy within 4 weeks before randomization
- Systemic biological therapy within 12 weeks or 5 half-lives before randomization
- Topical anti-psoriatic treatment within 2 weeks before randomization
- Physical therapy like phototherapy within 4 weeks before randomization
- Systemic anti-infective treatment within 4 weeks before randomization or active infections
- Serious, progressive, or uncontrolled diseases including immune, endocrine, hematological, urinary, liver, respiratory, nervous, psychiatric, cardiovascular, gastrointestinal, infectious diseases, or cancer
- Elevated serum creatinine or liver enzymes above specified limits at screening
- Participation in other clinical trials or use of investigational drugs within 1 month before screening
- Hypersensitivity to study drug components
- History of smoking, alcohol, or drug abuse
- Plans for pregnancy from 2 weeks before first dose to 1 month after last dose without effective contraception
- Other conditions deemed unsuitable by the investigator such as other skin problems, compliance issues, or inability to complete study requirements
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 12 locations
1
Beijing traditional Chinese medicine hospital affiliated to Capital Medical University
Beijing, China
Actively Recruiting
2
Affiliated Hospital of Changchun University of Traditional Chinese Medicine
Changchun, China
Actively Recruiting
3
The First Affiliated Hospital of Hunan University of Chinese Medicine
Changsha, China
Actively Recruiting
4
Chengdu Second People's Hospital
Chengdu, China
Actively Recruiting
5
Affiliated Hospital of Shandong University of Traditional Chinese Medicine
Jinan, China
Actively Recruiting
6
Yunnan Provincial Hospital of Traditional Chinese Medicine
Kunming, China
Actively Recruiting
7
Nanyang First People's Hospital
Nanyang, China
Actively Recruiting
8
The First Affiliated Hospital of China Medical University
Shenyang, China
Actively Recruiting
9
Affiliated Hospital of Tianjin Institute of Traditional Chinese Medicine
Tianjin, China
Actively Recruiting
10
First affiliated hospital of Wenzhou medical university
Wenzhou, China
Actively Recruiting
11
The Second Affiliated Hospital of Xiamen Medical College
Xiamen, China
Actively Recruiting
12
Xingtai people's hospital
Xingtai, China
Actively Recruiting
Research Team
R
Rui Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here